Overview
My primary research interest has focused on on novel therapeutics, biomarkers and clinical trial development for ovarian and endometrial cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division, where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically, my focus is on biologic therapy and molecular biomarkers to direct therapy in patients with ovarian and endometrial cancers to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian and cervical cancers, as well as for benign gynecologic conditions.
Current Appointments & Affiliations
Recent Publications
Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.
Journal Article Int J Gynecol Cancer · May 2025 OBJECTIVE: Next-generation sequencing and tumor testing to direct therapy in advanced/recurrent endometrial cancer are frequently used, but the impact of this approach is unclear. We sought to confirm the proportion of patients with at least 1 actionable a ... Full text Link to item CiteA new vision for women's health research at the National Institutes of Health from the National Academies of Sciences, Engineering, and Medicine's Consensus Report: potential impact for gynecologic cancer care and research.
Journal Article Int J Gynecol Cancer · April 2025 Full text Link to item CiteThe efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.
Journal Article Ann Oncol · March 2025 BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class, folate receptor alpha (FRα)-targeting antibody-drug conjugate with United States Food and Drug Administration approval for FRα-positive platinum-resistant ovarian cancer. PICCOLO is a p ... Full text Link to item CiteRecent Grants
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL1-23 in Women with Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6
Clinical TrialPrincipal Investigator · Awarded by TORL BioTherapeutics, LLC · 2025 - 2030A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme · 2025 - 2030A Phase 3 Randomized, Open-label Study of RinatabartSesutecan (Rina-S) versus Treatment of Investigator's Choice (IC) in Patients with Platinum Resistant Ovarian Cancer
Clinical TrialPrincipal Investigator · Awarded by Genmab US, Inc. · 2025 - 2030View All Grants